Dr. Irene Griswold-Prenner was previously a cofounder and CSO of Imago Pharmaceuticals. Imago engaged in development of drug candidates directed against the c-Jun N-terminal kinase (JNK) for fibrosis and neurodegenerative disease treatment. She previously led iPierian’s research efforts, where the first tau therapeutic antibody to begin human testing was developed. IPN007 has now been purchased by Biogen and is progressing in Phase II studies for progressive supranuclear palsy and Alzheimer’s disease. IPN007 is also the first drug in clinical trials where the discovery originated from an iPSC approach. Previously, Dr. Griswold-Prenner worked at Elan Pharmaceuticals and contributed to Alzheimer’s disease, Parkinson’s disease and multiple sclerosis programs.  She received her BA from Colorado University in molecular, cellular and developmental biology and her PhD from University of Chicago in physiology and cellular pharmacology.